Erasca Hosts Virtual Investor Event on Updated ERAS-0015 Phase 1 Data

By Public Technologies
  • Erasca will host a virtual investor event on Nov. 20, 2026, at 8 a.m. Eastern Time.
  • The event will focus on updated Phase 1 data for ERAS-0015 in RAS-mutant solid tumors.
  • Clinical ERAS-0015 data will also feature at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Nov. 18-20, 2026, in Barcelona.
  • A symposium poster presentation will cover nonclinical combination data for ERAS-0015 and ERAS-4001.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160801PRIMZONEFULLFEED9877913) on November 16, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk